| Autor: |
Vishakante Gowda D, Mahendran Bhaskaran, Akkihebbal R Akhila, Parthasarathi K. Kulkarni, Vikas Jain, Arun Kumar Vadikari |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
International Journal of Research in Pharmaceutical Sciences. 11:519-531 |
| ISSN: |
0975-7538 |
| Popis: |
Gastric Cancer (GC) is one among the serious diseases prevailing globally. GC has immense global life-threatening health issues by taking 4th place among all the widespread cancers and 2nd foremost reason for fatality around the globe. Numerous patients have an inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Surgery remains the principle therapy, while perioperative and adjuvant chemotherapy and chemoradiation can improve the outcome of GC therapy. Targeted therapies such as Trastuzumab, an antibody against HER2 and the VEGFR-2 antibody ramucirumab highly preferred in GC. Since the last few years, immunotherapy became a significant approach for the cure of various cancers like GC. In the present review, we have put forward the various stages of GC and all the possible advanced treatments for GC. Surgery is still the first choice analysed in GC followed by chemotherapy and radiotherapy. New frontiers in treatment suggest the growing consideration for intraperitoneal administration of chemotherapeutics and a combination of traditional drugs with the newer generation. A note is added to relevant studies dealing with neoadjuvant and adjuvant treatment concepts and gives an overview of latest trends and developments in GC treatment |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
